Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
22. November 2024 18:23 ET
|
Elevai Labs Inc.
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
22. November 2024 17:00 ET
|
Elevai Labs Inc.
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
CORRECTION - Elevai Labs Inc.
14. November 2024 14:35 ET
|
Elevai Labs Inc.
/CORRECTION/ Elevai Labs Inc. Reports Financial Results for the Third Fiscal Quarter of 2024 and Provides Business Update
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
14. November 2024 09:08 ET
|
Elevai Labs Inc.
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
04. November 2024 17:45 ET
|
Elevai Labs Inc.
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
22. Oktober 2024 09:54 ET
|
Elevai Labs Inc.
Elevai Biosciences Engages Leading CRO to Support Regulatory Planning Efforts and Pre-IND Meeting with the FDA for EL-22 For The Treatment of Obesity
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
21. Oktober 2024 07:30 ET
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
04. Oktober 2024 17:08 ET
|
Elevai Labs Inc.
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
03. Oktober 2024 15:45 ET
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
03. Oktober 2024 07:30 ET
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,